NSD2 and plasma cell myeloma: Previous studies have also validated CLEC11A as a novel regulator and candidate therapeutic target of multiple myeloma SET domain (MMSET)-related myeloma (16, 26, 27). These outcomes indicated that CLEC11A plays a vital role in hematopoietic regulation.